Moroctocog alfa
ReFacto (moroctocog alfa) is a protein pharmaceutical. Moroctocog alfa was first approved as Refacto af on 1999-04-13. It has been approved in Europe to treat hemophilia a.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 17 | 13 | 40 | 26 | 36 | 125 |
| Von willebrand diseases | D014842 | D68.0 | 1 | 1 | 6 | 1 | — | 9 | |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | 1 | 1 | 2 | 4 |
| Hemophilia b | D002836 | D67 | — | — | 1 | 1 | 1 | 3 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | 2 | 1 | 3 |
| Blood platelet disorders | D001791 | — | — | — | 1 | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Joint diseases | D007592 | HP_0003040 | M12.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MOROCTOCOG ALFA |
| INN | moroctocog alfa |
| Description | Moroctocog alfa (trade name ReFacto in the EU) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein. It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII). It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 284036-24-4 |
| RxCUI | 1300485 |
| ChEMBL ID | CHEMBL2109137 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13999 |
| UNII ID | 113E3Z3CJJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Refacto - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 246 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
28,053 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more